Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment
Objective Low-grade immune activation is common in people living with HIV (PLHIV), despite long-term viral suppression by antiretroviral therapy (ART). The clinical significance of this activation remains unclear. The aim of this study was to examine […]
CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study
CINAMMON is a phase IV, open-label, single-arm, pilot study assessing maraviroc (MVC) in the central nervous system (CNS) when added to darunavir/ritonavir monotherapy (DRV/r) in virologically suppressed HIV-infected subjects. CCR5 tropic participants on DRV/r were recruited. […]
Effects of Recent Alcohol Consumption Level on Neurocognitive Performance in HIV+ Individuals
Objectives: Although HIV+ individuals may be at increased risk of alcohol-related cognitive impairment, the relations between drinking level and cognitive performance in these individuals are not well understood. We examined whether higher levels of recent drinking […]
HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment
HIV-associated neurocognitive disorders (HAND) remain prevalent despite plasma viral suppression by antiretroviral agents. In fact, the prevalence of milder subtypes of cognitive impairment is increasing. Neuropsychologic testing remains the “gold standard” of diagnosis; however, this is […]
Does efavirenz replacement improve neurological function in treated HIV infection?
Objectives: The contribution of specific antiretroviral drugs to cognitive function in HIV-infected people remains poorly understood. Efavirenz (EFV) may plausibly cause cognitive impairment. The objective of this study was therefore to determine whether chronic EFV therapy […]
